The Utilisation of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer

Shenling Wang

2025

Abstract

For several years, surgical intervention and chemotherapy have been employed to address triple-negative breast cancer (TNBC), a heterogeneous subtype of invasive breast carcinoma. In recent years, FDA has sanctioned CTLA-4 monoclonal antibodies (mAbs) such as ipilimumab, along with PD-1/PD-L1 mAbs like pembrolizumab and atezolizumab, for the therapeutic management of multiple solid tumours, prompted by research on immune checkpoints including CTLA-4 and PD-1/PD-L1. The combination of PD-1/PD-L1 inhibitors with chemotherapy has demonstrated efficacy in the treatment of both early-stage and metastatic TNBC when immune checkpoint inhibitors (ICIs) are employed. This article compiles the mechanisms of PD-1/PD-L1 and CTLA-4 as ICIs, along with their research on monotherapy in TNBC. It also discussed how combination therapies, which include CTLA-4 and PD-1/PD-L1 inhibitors, as well as chemotherapy and immunomodulatory drugs (ICIs) can be utilised to treat TNBC. A summary of the negative outcomes of immunotherapy was also provided.

Paper Citation

in Harvard Style

Wang S. (2025). The Utilisation of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. In Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS; ISBN 978-989-758-789-4, SciTePress, pages 168-173. DOI: 10.5220/0014440100004933

in Bibtex Style

@conference{befs25,
author={Shenling Wang},
title={The Utilisation of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer},
booktitle={Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS},
year={2025},
pages={168-173},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0014440100004933},
isbn={978-989-758-789-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS
TI - The Utilisation of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
SN - 978-989-758-789-4
AU - Wang S.
PY - 2025
SP - 168
EP - 173
DO - 10.5220/0014440100004933
PB - SciTePress